secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001485003-23-000099
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio to pay $0.36/share special dividend and issue CVR upon merger close on March 7
--------------------------------------------------------------------------------

- Special cash dividend of $75M (~$0.36/share) payable by March 10 to holders of record March 7, contingent on merger closing.
- Each share receives one Contingent Value Right for potential proceeds from sale of Vicineum/preclinical assets and Roche milestone.
- Merger with CARISMA Therapeutics approved by stockholders on March 2, expected to close March 7.
- Dividend and CVR issuance contingent on closing of merger with CARISMA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000099/0001485003-23-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000099/sesn-20230306.htm
  HTML page:      https://secwatch.observer/filing/0001485003-23-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer